Suppr超能文献

评估儿童重度治疗抵抗性哮喘:诊断和治疗策略。

Evaluating Severe Therapy-Resistant Asthma in Children: Diagnostic and Therapeutic Strategies.

机构信息

Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.

出版信息

Medicina (Kaunas). 2024 Nov 2;60(11):1799. doi: 10.3390/medicina60111799.

Abstract

: Worldwide, asthma is the most common non-communicable respiratory disease and causes considerable morbidity and mortality. Most people with asthma can be treated effectively with low-dose medications if these are taken correctly and regularly. Around 10% of people with asthma have an uncontrolled form of the disease or can only achieve control with high-dose medications, incurring disproportionately high health care costs. : PubMed and personal archives were searched for relevant articles on the definition, management and pharmacotherapy of severe asthma. The WHO classification of severe asthma and the treatment levels encompassed in the definition are discussed. Most children and young people referred for consideration of 'beyond-guidelines therapy' can in fact be managed on standard treatment after a multi-disciplinary team assessment focusing on ensuring correct basic management, and these steps are described in detail. Options for those with true therapy-resistant asthma are described. These include monoclonal antibodies, most of which target type 2 inflammation. : Getting the basics right is still the most important aspect of asthma care. For those with severe, therapy-resistant asthma, an increasing number of life-transforming monoclonals have been developed, but there is still little understanding of, and a paucity of treatment options for, non-eosinophilic asthma.

摘要

: 在全球范围内,哮喘是最常见的非传染性呼吸系统疾病,可导致相当高的发病率和死亡率。如果正确且定期使用低剂量药物,大多数哮喘患者都可以得到有效治疗。大约 10%的哮喘患者患有控制不佳的疾病,或者只能使用高剂量药物来控制,从而导致不成比例的高医疗费用。: 检索了关于严重哮喘的定义、管理和药物治疗的相关文献,包括在 PubMed 和个人档案中。讨论了世界卫生组织(WHO)对严重哮喘的分类和定义中包含的治疗级别。大多数因“超越指南治疗”而被转介考虑的儿童和年轻人,实际上可以在多学科团队评估后,通过专注于确保正确基本管理的标准治疗来进行管理,并且详细描述了这些步骤。还描述了那些真正对治疗有抵抗的哮喘患者的选择。这些包括针对 2 型炎症的单克隆抗体,其中大多数。: 正确把握基础仍然是哮喘护理最重要的方面。对于那些患有严重、治疗抵抗性哮喘的患者,已经开发出越来越多可以改变生活的单克隆抗体,但对于非嗜酸性粒细胞性哮喘,人们的了解仍然很少,并且治疗选择也很少。

相似文献

2
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].[支气管哮喘防治指南(2024年版)]
Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601.
4
Diagnosis and Management of Problematic Severe Asthma.《难治性重度哮喘的诊断与管理》
Acta Med Acad. 2020 Aug;49(2):117-129. doi: 10.5644/ama2006-124.291.
5
The management of severe asthma in 2020.2020 年严重哮喘的管理。
Biochem Pharmacol. 2020 Sep;179:114112. doi: 10.1016/j.bcp.2020.114112. Epub 2020 Jun 27.
6
Management of severe asthma in children.儿童严重哮喘的管理。
Lancet. 2010 Sep 4;376(9743):814-25. doi: 10.1016/S0140-6736(10)61054-9.

本文引用的文献

1
The new biologic drugs: Which children with asthma should get what?新型生物制剂:哪些哮喘患儿应使用何种药物?
Pediatr Pulmonol. 2024 Dec;59(12):3057-3074. doi: 10.1002/ppul.27218. Epub 2024 Sep 13.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验